Bessemer Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$122M Sell
5,067,281
-97,810
-2% -$2.56M 0.17% 151
2026
Q1
$145M Buy
5,165,091
+5,028,603
+3,684% +$134M 0.23% 108
2025
Q4
$3.4M Buy
136,488
+6,727
+5% +$170K 0.01% 572
2025
Q3
$3.31M Buy
129,761
+6,896
+6% +$170K 0.01% 412
2025
Q2
$2.98M Sell
122,865
-9,613
-7% -$224K ﹤0.01% 413
2025
Q1
$3.36M Buy
132,478
+13,228
+11% +$346K 0.01% 402
2024
Q4
$3.16M Sell
119,250
-21,371
-15% -$580K 0.01% 546
2024
Q3
$4.07M Sell
140,621
-8,299
-6% -$242K 0.01% 477
2024
Q2
$4.17M Buy
148,920
+6,574
+5% +$181K 0.01% 393
2024
Q1
$3.95M Sell
142,346
-30,560
-18% -$848K 0.01% 419
2023
Q4
$4.98M Sell
172,906
-51,022
-23% -$1.54M 0.01% 370
2023
Q3
$7.43M Sell
223,928
-14,069
-6% -$498K 0.02% 305
2023
Q2
$8.73M Buy
237,997
+21,387
+10% +$832K 0.02% 275
2023
Q1
$8.84M Sell
216,610
-7,702
-3% -$333K 0.02% 267
2022
Q4
$11.5M Sell
224,312
-12,502
-5% -$599K 0.03% 239
2022
Q3
$10.4M Buy
236,814
+13,146
+6% +$639K 0.03% 239
2022
Q2
$11.7M Sell
223,668
-4,845
-2% -$247K 0.03% 217
2022
Q1
$11.8M Buy
228,513
+27,844
+14% +$1.44M 0.02% 209
2021
Q4
$11.8M Buy
200,669
+28,928
+17% +$1.43M 0.02% 203
2021
Q3
$7.39M Sell
171,741
-337
-0.2% -$14.9K 0.02% 231
2021
Q2
$6.74M Sell
172,078
-747
-0.4% -$29K 0.01% 239
2021
Q1
$6.26M Sell
172,825
-32,588
-16% -$1.16M 0.02% 245
2020
Q4
$7.56M Sell
205,413
-16,506
-7% -$605K 0.02% 225
2020
Q3
$7.73M Sell
221,919
-86,240
-28% -$3.02M 0.02% 227
2020
Q2
$9.56M Buy
308,159
+92,873
+43% +$3.16M 0.03% 252
2020
Q1
$6.67M Buy
215,286
+20,352
+10% +$693K 0.03% 263
2019
Q4
$7.25M Buy
194,934
+25,018
+15% +$891K 0.02% 277
2019
Q3
$5.79M Sell
169,916
-8,945,037
-98% -$325M 0.02% 264
2019
Q2
$375M Sell
9,114,953
-24,690
-0.3% -$980K 1.26% 14
2019
Q1
$368M Buy
9,139,643
+37,670
+0.4% +$1.51M 1.41% 10
2018
Q4
$377M Buy
9,101,973
+2,391,534
+36% +$99.3M 1.64% 6
2018
Q3
$281M Buy
6,710,439
+6,540,368
+3,846% +$252M 1.04% 23
2018
Q2
$5.86M Buy
170,071
+19,375
+13% +$662K 0.02% 255
2018
Q1
$5.08M Sell
150,696
-562,322
-79% -$19.3M 0.02% 290
2017
Q4
$24.5M Sell
713,018
-524,391
-42% -$17.9M 0.1% 142
2017
Q3
$41.9M Buy
1,237,409
+21,980
+2% +$706K 0.17% 125
2017
Q2
$38.7M Buy
1,215,429
+14,253
+1% +$449K 0.16% 124
2017
Q1
$39M Sell
1,201,176
-3,969,668
-77% -$125M 0.16% 129
2016
Q4
$159M Buy
5,170,844
+24,025
+0.5% +$733K 0.73% 35
2016
Q3
$165M Sell
5,146,819
-113,672
-2% -$3.8M 0.83% 30
2016
Q2
$176M Sell
5,260,491
-1,758,362
-25% -$56.1M 0.96% 21
2016
Q1
$197M Buy
7,018,853
+139,184
+2% +$3.98M 1.11% 15
2015
Q4
$211M Buy
6,879,669
+15,898
+0.2% +$500K 1.17% 13
2015
Q3
$205M Buy
6,863,771
+53,341
+0.8% +$1.71M 1.17% 13
2015
Q2
$217M Sell
6,810,430
-1,722,577
-20% -$56.1M 1.13% 12
2015
Q1
$282M Buy
8,533,007
+6,183
+0.1% +$197K 1.43% 7
2014
Q4
$252M Buy
8,526,824
+6,625
+0.1% +$190K 1.36% 9
2014
Q3
$239M Buy
8,520,199
+111,459
+1% +$3.13M 1.36% 9
2014
Q2
$237M Buy
8,408,740
+1,352,656
+19% +$38.6M 1.46% 8
2014
Q1
$215M Buy
7,056,084
+437,296
+7% +$13M 1.45% 6
2013
Q4
$192M Buy
6,618,788
+187,689
+3% +$5.46M 1.38% 7
2013
Q3
$175M Buy
6,431,099
+101,919
+2% +$2.77M 1.42% 7
2013
Q2
$168M Buy
+6,329,180
New +$175M 1.51% 3

Other funds holding PFE

Bessemer Group's PFE Position: Q2 2026 in Review

Bessemer Group reduced its Pfizer (PFE) stake by 1.9% in Q2 2026, selling an estimated $2.56M and leaving 5,067,281 shares worth $122M. The position accounts for 0.17% of the portfolio, ranked #151.

Bessemer Group first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $377M in Q4 2018. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Bessemer Group held 5,067,281 shares of Pfizer worth $122M as of Q2 2026.
  • Bessemer Group sold 97,810 Pfizer shares in Q2 2026, an estimated $2.56M.
  • Pfizer made up 0.17% of Bessemer Group's portfolio in Q2 2026, its #151 holding.
  • Bessemer Group first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Bessemer Group's Pfizer position peaked at $377M in Q4 2018.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.